TG Therapeutics
TGTX
244 hedge funds and large institutions have $2.19B invested in TG Therapeutics in 2023 Q2 according to their latest regulatory filings, with 61 funds opening new positions, 73 increasing their positions, 72 reducing their positions, and 31 closing their positions.
97% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 31
54% more capital invested
Capital invested by funds: $1.42B → $2.19B (+$770M)
47% more call options, than puts
Call options by funds: $144M | Put options by funds: $97.6M
14% more funds holding
Funds holding: 214 → 244 (+30)
1% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 72
5.67% less ownership
Funds ownership: 64.83% → 59.17% (-5.7%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
+$42M |
| 2 |
BlackRock
New York
|
+$27.6M |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$23.2M |
| 4 |
D.E. Shaw & Co
New York
|
+$19.2M |
| 5 |
Man Group
London,
United Kingdom
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JFG
Jefferies Financial Group
New York
|
-$76.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$52.1M |
| 3 |
Millennium Management
New York
|
-$46.3M |
| 4 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$30.3M |
| 5 |
Alkeon Capital Management
New York
|
-$29.5M |
TGTX Hedge Fund Activity: Q2 2023 in Review
244 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q2 2023, worth a combined $2.19B — up 54% from $1.42B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new TGTX positions and 31 closed out — a net gain of 30 holders — while 73 added to existing stakes and 72 trimmed.
The largest buyer was Holocene Advisors, opening a new position worth an estimated $42M. The largest seller was Jefferies Financial Group, exiting entirely with an estimated $76.7M sold.
- 244 institutional investors held TG Therapeutics (TGTX) as of Q2 2023, up from 214 in Q1 2023.
- Funds reported $2.19B of TG Therapeutics stock for Q2 2023, up 54% quarter-over-quarter.
- 61 funds opened new TG Therapeutics positions in Q2 2023 and 31 closed out, a net change of +30 holders.
- The largest TG Therapeutics buyer in Q2 2023 was Holocene Advisors, an estimated $42M added.
- The largest TG Therapeutics seller in Q2 2023 was Jefferies Financial Group, an estimated $76.7M sold.
Based on aggregated 13F filings for Q2 2023.